Structure Therapeutics said on Wednesday that it expects oral weight-loss drugs to capture 25% to 50% of the GLP-1 market by 2030, a bullish estimate the CEO said was driven partly by pent-up demand ...
Within eight months, states must show the money they received through the Rural Health Transformation Program is going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback